Pomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc. and Certain Officers – INO

Pomerantz LLP has filed a class action lawsuit against Inovio Pharmaceuticals and certain officers for alleged securities fraud. The lawsuit claims defendants made false statements about FDA approval prospects and manufacturing capabilities for their lead product INO-3107. The company delayed BLA submission by a year due to manufacturing issues with the CELLECTRA device, and the FDA rejected accelerated approval eligibility. Stock fell 24.45% on the December 2025 announcement.

04/07/2026, 3:46 PM • GlobeNewswire

DEADLINE ALERT for PSFE, INO, KD: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

Law Offices of Howard G. Smith announced securities fraud class action lawsuits against three publicly-traded companies: Paysafe Limited (PSFE) for undisclosed business risks and overstated guidance, Inovio Pharmaceuticals (INO) for deficient manufacturing and overstated regulatory prospects, and Kyndryl Holdings (KD) for misstated financial statements and inadequate internal controls. Lead plaintiff deadlines range from April 7-13, 2026.

04/07/2026, 12:00 PM • GlobeNewswire

Bragar Eagel & Squire, P.C. Urgently Reminds Investors that a Class Action Lawsuit Has Been Filed Against Inovio Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm Before April 7th

A class action lawsuit has been filed against Inovio Pharmaceuticals for allegedly making false and misleading statements regarding manufacturing deficiencies in its CELLECTRA device and overstating regulatory prospects for INO-3107. The FDA accepted Inovio's BLA on a standard review timeline rather than accelerated approval, causing the stock to fall 24.45% on December 29, 2025. Investors who purchased shares between October 10, 2023 and December 26, 2025 can join the lawsuit with a deadline of April 7, 2026.

04/06/2026, 5:38 PM • GlobeNewswire

Shareholders that lost money on Atara Biotherapeutics, Inc.(ATRA) should contact Levi & Korsinsky about pending Class Action - ATRA

Law firm Levi & Korsinsky announced multiple pending class action securities lawsuits on April 6, 2026. The primary case involves Atara Biotherapeutics (ATRA), alleging securities fraud between May 2024 and January 2026 related to manufacturing issues and overstated regulatory prospects for tabelecleucel. Investors who suffered losses during this period can request lead plaintiff status by May 22, 2026. Additional lawsuits were filed against Camping World Holdings (CWH) for alleged inventory valuation inflation and Inovio Pharmaceuticals (INO).

04/06/2026, 4:00 PM • GlobeNewswire

UNIQURE DEADLINE: ROSEN, A LEADING AND LONGSTANDING FIRM, Encourages uniQure N.V. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 13 Deadline in Securities Class Action - QURE

Rosen Law Firm is notifying investors in uniQure N.V., Inovio Pharmaceuticals, and Masonite International Corporation of upcoming lead plaintiff deadlines in securities class action lawsuits. uniQure faces allegations of misrepresenting FDA approval status of its Pivotal Study and downplaying delays to its Biologics License Application timeline. Investors with losses exceeding $100K are encouraged to seek counsel before the respective deadlines.

04/05/2026, 9:32 PM • GlobeNewswire

INO FINAL DEADLINE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Inovio Pharmaceuticals Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 7 Deadline in Securities Class Action – INO

Rosen Law Firm is notifying investors in Inovio Pharmaceuticals, uniQure N.V., and Masonite International Corporation of upcoming lead plaintiff deadlines in securities class action lawsuits. Inovio faces allegations of false statements regarding manufacturing deficiencies and overstated regulatory prospects for its INO-3107 product. Investors with losses exceeding $100K are encouraged to seek counsel before the respective deadlines.

04/05/2026, 9:27 PM • GlobeNewswire

Deadline Alert: Inovio Pharmaceuticals, Inc. (INO) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

Inovio Pharmaceuticals faces a securities fraud class action lawsuit covering the period from October 10, 2023 to December 26, 2025. The lawsuit alleges the company made false statements about its INO-3107 treatment's regulatory timeline and prospects, citing manufacturing deficiencies with its CELLECTRA device. Stock prices fell significantly following disclosures in August 2024 (3.1% decline) and December 2025 (24.45% decline) regarding delayed FDA submissions and rejection of accelerated review status. The deadline to file a lead plaintiff motion is April 7, 2026.

04/03/2026, 12:44 PM • GlobeNewswire

INO FINAL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Inovio Pharmaceuticals Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 7 Deadline in Securities Class Action – INO

Rosen Law Firm reminds investors of Inovio Pharmaceuticals who suffered losses exceeding $100K during October 10, 2023 to December 26, 2025 of the April 7, 2026 lead plaintiff deadline. The lawsuit alleges defendants made false statements regarding manufacturing deficiencies in the CELLECTRA device, overstating INO-3107's regulatory prospects and FDA approval timeline.

04/02/2026, 4:46 PM • GlobeNewswire

ROSEN, THE FIRST FILING FIRM, Encourages Trip.com Group Limited Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - TCOM

Rosen Law Firm has filed securities class action lawsuits against Trip.com Group Limited, Inovio Pharmaceuticals Inc., and Super Micro Computer Inc., alleging that defendants made false and misleading statements regarding business operations and regulatory risks. Investors who purchased securities during specified class periods are encouraged to secure counsel before upcoming deadlines.

04/02/2026, 4:30 PM • GlobeNewswire

ROSEN, THE FIRST FILING FIRM, Encourages Kyndryl Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – KD

Rosen Law Firm is soliciting investors who purchased securities in Kyndryl Holdings, Alight Inc., and Inovio Pharmaceuticals during specified periods to join class action lawsuits. The lawsuits allege that these companies made false statements, failed to disclose material information, and had inadequate internal controls, resulting in investor losses.

03/30/2026, 6:52 PM • GlobeNewswire

INOVIO DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Inovio Pharmaceuticals Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 7 Deadline in Securities Class Action – INO

Rosen Law Firm is reminding investors in Inovio Pharmaceuticals who suffered losses exceeding $100,000 to secure legal counsel before the April 7, 2026 deadline for the securities class action. The lawsuit alleges that Inovio made false statements regarding manufacturing deficiencies in its CELLECTRA device and overstated regulatory prospects for its INO-3107 drug candidate, causing investor damages when the truth emerged.

03/30/2026, 6:42 PM • GlobeNewswire

Bronstein, Gewirtz & Grossman LLC Urges Inovio Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Inovio Pharmaceuticals alleging that company executives made materially false and misleading statements regarding the CELLECTRA device manufacturing, INO-3107 BLA submission timeline, and regulatory prospects between October 2023 and December 2025. Investors who purchased Inovio securities during this period are encouraged to join the case, with a lead plaintiff deadline of April 7, 2026.

03/30/2026, 12:00 PM • GlobeNewswire

INO DEADLINE ALERT: ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Inovio Pharmaceuticals Inc. Investors to Secure Counsel Before Important April 7 Deadline in Securities Class Action – INO

Rosen Law Firm is alerting investors in Inovio Pharmaceuticals who purchased securities between October 10, 2023 and December 26, 2025 of an April 7, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Inovio made false and misleading statements regarding manufacturing deficiencies in its CELLECTRA device, overstating regulatory prospects for its INO-3107 drug candidate and its likelihood of FDA submission.

03/24/2026, 6:51 PM • GlobeNewswire

Pomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc.and Certain Officers – INO

Pomerantz LLP has filed a class action lawsuit against Inovio Pharmaceuticals for alleged securities fraud. The lawsuit claims Inovio made false statements about FDA approval prospects and manufacturing capabilities for its lead product INO-3107. The company delayed its BLA submission by a year due to manufacturing issues with its CELLECTRA device, and the FDA rejected accelerated approval status. Stock fell 3.1% on the first disclosure and 24.45% on the FDA decision.

03/24/2026, 3:53 PM • GlobeNewswire

Levi & Korsinsky, LLP: Fraud-On-The-Market Doctrine Underpins Inovio Pharmaceuticals Securities Class Action

Levi & Korsinsky, LLP is representing investors in a securities class action against Inovio Pharmaceuticals for allegedly making false or misleading statements about device manufacturing and FDA regulatory pathways between October 10, 2023 and December 26, 2025. The lawsuit relies on the fraud-on-the-market doctrine, which presumes that misrepresentations were incorporated into the stock price on the efficient NASDAQ market, artificially inflating it.

03/23/2026, 4:00 PM • GlobeNewswire